Camurus CAMX.SE | STOCKHOLM Exch | Medical-Diversified | MktCap SEK42.03B Sales SEK2.27B | Shares 60M Float 39M | EPS Due in 72 Days (e)

46462865730
EPS Rank 99

camurus.com — Lund, SWEDEN Inc 2004 — MGMT owns --

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines.
MORE

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024
EPS SEK	-1.99	-4.68	-5.68	-6.23	-3.18	-1.66	1.01	7.78	7.39
CASH FLOW/SHR SEK	-5.10	-4.99	-6.63	-8.70	-4.53	-2.63	1.84	10.55	6.52
PRETAX MARGIN %	-91%	-448%	-582%	-342%	-62%	-19%	8%	32%	30%
RETURN ON EQUITY %	-13%	-40%	-74%	-66%	-23%	-11%	6%	35%	18%
SALES % CHANGE	-27%	-52%	-9%	114%	218%	79%	59%	80%	9%
SALES (MIL) SEK	114	54	49	106	336	601	956	1,717	1,868
WEEKLY	**4 Jul**	**11 Jul**	**18 Jul**	**25 Jul**	**1 Aug**	**8 Aug**	**15 Aug**	**22 Aug**	**25 Aug**
DATAGRAPH RATING	71	71	78	78	77	74	75	79	78
AVG DAILY VOL (000)	220	224	232	229	204	198	176	153	99
UP DOWN VOLUME	0.5	0.4	0.5	0.5	0.6	0.7	0.5	0.5	1.3
ACCUM/DIST RATING	-30	-15	-14	-3	-12	-17	-17	-18	-18
RELATIVE STRENGTH	65	66	73	70	63	49	66	76	76
GROUP RANK	91	99	91	81	70	75	59	63	70

2025 Estimate	2026 Estimate
14.63 98%	24.82 70%

Earnings Growth Rate	Sales Growth Rate
2023-25 129% (84 Stability)	39%
2021-25 129% (84 Stability)	58%

COMP RATING 97 — SMR RATING A

INV T/O 1.1x 41				
DEBT %	2022-24	1.7%	0.91%	0.22%
TAX RATE	2022-24	24%	21%	22%
BACKLOG	2022-24	--	--	--
R & D	36.50%	BK VAL 12.43x '24		
DIV SEK	None	DIV GR RT--		
BETA	0.83(9.00)	ALPHA 0.02 (0.01)		
2024 EMPLOYEES 256	(20%)			

Best-possible EPS Rank 99

Improving Up/Down Volume ratio and RS Rating

The stock is back in its pivot range after bouncing off its 50-DMA. Next support is at its rising 21-DMA (SEK 673.35), followed by its 50-DMA (SEK 658.84)

Strong fundamental profile, with SMR Rating of A and Composite Rating of 97. Double-digit earnings growth estimates for 2025 and 2026

RS line is trending upward, with an RS Rating of 76



FINANCIALS	, 20	Dec, 20	Mar, 21	Jun, 21	Sep, 21	Dec, 21	Mar, 22	Jun, 22	Sep, 22	Dec, 22	Mar, 23	Jun, 23	Sep, 23	Dec, 23	Mar, 24	Jun, 24	Sep, 24	Dec, 24	Mar, 25	Jun, 25	Sep,
EPS (SEK)	.38	-1.22	-0.40	-0.89	-0.11	-0.26	-0.01	0.15	0.63	0.24	1.06	5.44	1.56	-0.27	1.36	1.28	2.21	2.50	3.35	4.15	3.52e
EPS % CHANGE	1%	+17%	+66%	-128%	+71%	+79%	+98%	+117%	+673%	+192%	+11K%	+4K%	+148%	-212%	+28%	-76%	+42%	+1K%	+146%	+224%	+59%e
SALES (MIL SEK)	0.3	105.6	125.9	137.9	154.0	182.8	220.3	226.7	241.4	268.0	284.0	674.3	384.0	374.6	390.0	444.9	479.6	553.1	558.3	675.5	625.2e
SALES % CHANGE	0%	+201%	+155%	+71%	+54%	+73%	+75%	+64%	+57%	+47%	+29%	+197%	+59%	+40%	+37%	-34%	+25%	+48%	+43%	+52%	+30%e
MARGIN AFTER TAX	2%	-62.0%	-17.4%	-35.1%	-4.0%	-7.7%	-0.3%	+3.6%	+14.5%	+4.9%	+20.7%	+44.7%	+22.5%	-4.1%	+20.0%	+16.7%	+27.0%	+26.6%	+35.3%	+36.2%	
P/E LOW-HIGH									366-510	228-277	99-129	27-41	32-38	39-70	52-74	118-154	127-156	72-91	58-73	40-57	
FUNDS	44	63	79	84	80	75	72	80	90	106	108	111	129	214	247	273	301	277	273	272	

P/E	57
2025 Est.:	48.2
2026 Est.:	28.4
5-yr High:	510
5-yr Low:	27
vs Ind. Avg:	2.3x

PANARAY® 2025 WILLIAM O'NEIL + CO. INC.